Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2012Leukemia & lymphoma/Leukemia and lymphomaOpen Access

The evolving treatment paradigm in myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRuben A. MesaUniversity of Insubria

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ruben A. Mesa (2012) studied this question.

synapsesocial.com/papers/6aaa247a619ebc893b481535https://doi.org/10.3109/10428194.2012.710905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia1998 · 145 citations
  2. 2JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis2012 · 1,836 citations
  3. 3CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms2010 · 243 citations